Gilead Sciences to Invest Additional $320 Million in Arcus Biosciences, Increasing Stake to 33%

Gilead Sciences to Invest Additional $320 Million in Biopharmaceutical Company Arcus Biosciences, Increasing Stake to 33%. Gilead Sciences will gain a third seat on Arcus' board, to be held by Gilead’s Chief Commercial Officer, Johanna Mercier. (Cailian Press)Original Link